Resources for Physicians
The main aim and objective of the Action was to establish a European Network to further understand chronic GvHD, through networking and interdisciplinary training.
We offer existing resources, tools, videos and COST Action publications to provide the best care for our patients.
For the precise list of publications, see on the dedicated pages on this website, or follow the link.
General resources
General resources on cGVHD.
Quick, easy to use.
|
Awareness of GVHD |
|
|
cGVHD in a nutshell |
|
|
What you should talk about with your BMT patient |
Bone marrow transplantation.
What to know about bone marrow transplantation & where to look for information.
|
Reference manual of cellular therapy. Edition 2019 available in pdf. |
|
|
The European Society for Blood and Marrow Transplant (EBMT) Transplant Complications Working Party EBMT Transplantation complication working party |
|
|
The Centre for International Blood & Marrow Transplant Research (CIBMTR) GvHD working Group |
|
Existing online atlas on GvHD for professionals
|
Dermatology Net New Zealand (DermNet NZ) resource for skin disease information An roadmap to skin cGVHD |
|
|
The Fred Hutchinson Centre Video on Chronic GvHD assessments Video on Chronic GvHD assessments |
GvHD Definitions and Existing GvHD tools
Lee Chronic GvHD Symptom Scale: European Translations
The Lee cGvHD Symptom Scale is a validated and internationally recognized scale to measure symptoms of cGvHD. The original 30-item scale, using a 1-month recall period, was developed and published in 2002 (Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002;8(8):444–452. https://pubmed.ncbi.nlm.nih.gov/12234170/).
In 2020, a modified Lee cGvHD Symptom Scale, consisting of 28 items, and using a 7-day recall period was published (Teh C, Onstad L, Lee SJ. Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale. Biol Blood Marrow Transplant. 2020;26(3):562-567. https://pubmed.ncbi.nlm.nih.gov/31759158/).
To facilitate the use of the original or modified symptom scale in European countries, a EU COST Action EUROGRAFT project was launched by Prof. Hélène Schoemans from Belgium and Dr. Lars Klingen Gjærde from Denmark with the aim of developing European translations of the Symptom Scale. A research article about the project is pending. In brief, we requested translated versions of the Symptom Scale from persons from different European countries who had knowledge about allogeneic hematopoietic cell transplantation. Their translations were reverse-translated back to English using Google Translate and these files were subsequently reviewed and revised by another native speaker of the translated language. Based on their revisions, a final translated version were made, which are made freely available below in 14 different languages, in addition to the original English version, in a standardized format.
The translated document encompasses in a single file both the original and the modified version of the Symptom Scale. The text highlighted in yellow marks the difference between the two versions, i.e. the recall-period and the two items which were removed from the modified version (items k. and p.).
NIH 2020 Chronic GvHD Consensus Conference
|
2020 Chronic GVHD Consensus Conference Conference On Demand! |
|
|
2020 National Cancer Institute (NCI) GVHD Patient Advocacy Summit Webinar |
cGVHD caregivers
Take care of yourself, to take care of your loved-ones and your patients.
